KINDAI UNIVERSITY


※苗字と名前の間にスペースをあけ、入力してください

田村 孝雄タムラ タカオ

プロフィール

所属部署名奈良病院
職名教授
学位博士(医学)
専門腫瘍内科学・消化器腫瘍学、胃癌、大腸癌、食道癌
ジャンル医療・健康/がん治療
コメンテータガイドhttp://www.kindai.ac.jp/meikan/753-tamura-takao.html
ホームページURLhttp://kaken.nii.ac.jp/d/r/80324929.ja.html
メールアドレス
Last Updated :2017/09/14

コミュニケーション情報 byコメンテータガイド

コメント

    消化器癌の化学療法の臨床研究を専門としています。胃癌、大腸癌、食道癌、膵臓癌、胆管癌等の消化器癌の抗がん剤治療(分子標的薬や新薬を含む)や集学的治療の実際について。

学歴・経歴

学歴

  • 1982年04月 - 1988年03月, 神戸大学, 医学部

経歴

  •   2008年06月,  - 2012年03月, 近畿大学医学部奈良病院(准教授)
  •   2005年01月,  - 2008年05月, 神戸大学(講師)

研究活動情報

研究分野

  • 薬学, 医療系薬学

研究キーワード

  • 膵臓癌, 食道癌, 胃がん, フッ化ピリミジン系, がん化学療法, 大腸癌, 代謝拮抗剤, 適正使用

論文

  • Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil., Kobuchi S, Hayashi A, Taniguchi M, Ito Y, Tamura T, Sakaeda T, Cancer chemotherapy and pharmacology, 78, 3, 517, 523,   2016年09月, 査読有り
  • Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer., Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Yamaguchi K, Segawa Y, Omuro Y, Tamura T, Doi T, Yukisawa S, Yasui H, Nagashima F, Gotoh M, Esaki T, Emig M, Chandrawansa K, Liepa AM, Wilke H, Ichimiya Y, Ohtsu A, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 19, 3, 927, 938,   2016年07月, 査読有り
  • HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer., Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K., Oncotarget., 7, 3, 3453, 3460,   2016年01月, 査読有り
  • Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer., Ueda S, Kawakami H, Nishina S, Sakiyama T, Nonagase Y, Okabe T, Tamura T, Nakagawa K, Cancer chemotherapy and pharmacology, 76, 2, 279, 285,   2015年08月, 査読有り
  • Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer., Yonesaka K, Satoh T, Ueda S, Yoshida T, Takeda M, Shimizu T, Okamoto I, Nishio K, Tamura T, Nakagawa K, Anticancer research, 35, 3, 1683, 1689,   2015年03月, 査読有り
  • Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing., Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, De Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K, PloS one, 10, 5, e0121891,   2015年, 査読有り
  • Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer., Yonesaka K, Takegawa N, Satoh T, Ueda H, Yoshida T, Takeda M, Shimizu T, Chiba Y, Okamoto I, Nishio K, Tamura T, Nakagawa K, PloS one, 10, 11, e0143132,   2015年, 査読有り
  • The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells., Kawakami H, Okamoto I, Yonesaka K, Okamoto K, Shibata K, Shinkai Y, Sakamoto H, Kitano M, Tamura T, Nishio K, Nakagawa K, Oncotarget, 5, 23, 11847, 11856,   2014年12月, 査読有り
  • Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912., Takahari D, Boku N, Mizusawa J, Takashima A, Yamada Y, Yoshino T, Yamazaki K, Koizumi W, Fukase K, Yamaguchi K, Goto M, Nishina T, Tamura T, Tsuji A, Ohtsu A, The oncologist, 19, 4, 358, 366,   2014年04月, 査読有り
  • Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma., Minegaki T, Kuwahara A, Yamamori M, Nakamura T, Okuno T, Miki I, Omatsu H, Tamura T, Hirai M, Azuma T, Sakaeda T, Nishiguchi K, International journal of medical sciences, 11, 4, 321, 326,   2014年, 査読有り
  • Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection., Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K, PloS one, 9, 7, e101902,   2014年, 査読有り
  • Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study., Yamaguchi K, Sawaki A, Doi T, Satoh T, Yamada Y, Omuro Y, Nishina T, Boku N, Chin K, Hamamoto Y, Takiuchi H, Komatsu Y, Saji S, Koizumi W, Miyata Y, Sato A, Baba E, Tamura T, Abe T, Ohtsu A, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 16, 2, 175, 182,   2013年04月, 査読有り
  • TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma., Omatsu H, Kuwahara A, Yamamori M, Fujita M, Okuno T, Miki I, Tamura T, Nishiguchi K, Okamura N, Nakamura T, Azuma T, Hirano T, Ozawa K, Hirai M, International journal of medical sciences, 10, 12, 1755, 1760,   2013年, 査読有り
  • Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study., Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N, Miyata Y, Takiuchi H, Yamaguchi K, Sasaki Y, Nishina T, Satoh A, Baba E, Tamura T, Abe T, Hatake K, Ohtsu A, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 15, 3, 313, 322,   2012年07月, 査読有り
  • Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer., Satoh T, Omuro Y, Sasaki Y, Hamamoto Y, Boku N, Tamura T, Ohtsu A, Cancer chemotherapy and pharmacology, 69, 4, 949, 955,   2012年04月, 査読有り
  • Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations., Kadoyama K, Miki I, Tamura T, Brown JB, Sakaeda T, Okuno Y, International journal of medical sciences, 9, 1, 33, 39,   2012年, 査読有り
  • Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System., Tamura T, Sakaeda T, Kadoyama K, Okuno Y, International journal of medical sciences, 9, 5, 322, 326,   2012年, 査読有り
  • Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS., Tamura T, Sakaeda T, Kadoyama K, Okuno Y, International journal of medical sciences, 9, 6, 441, 446,   2012年, 査読有り
  • THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma., Miki I, Nakamura T, Kuwahara A, Yamamori M, Nishiguchi K, Tamura T, Okuno T, Omatsu H, Mizuno S, Hirai M, Azuma T, Sakaeda T, International journal of medical sciences, 9, 9, 748, 756,   2012年, 査読有り
  • VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma., Tamura T, Kuwahara A, Yamamori M, Nishiguchi K, Nakamura T, Okuno T, Miki I, Manabe Y, Sakaeda T, International journal of medical sciences, 9, 10, 833, 837,   2012年, 査読有り
  • Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma., Kuwahara A, Yamamori M, Kadoyama K, Nishiguchi K, Nakamura T, Miki I, Tamura T, Okuno T, Omatsu H, Sakaeda T, Journal of experimental & clinical cancer research : CR, 30, 94,   2011年10月, 査読有り
  • Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer., Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, Shiraishi Y, Nakata I, Nishiguchi K, Matsubayashi T, Takakubo Y, Okamura N, Yamamori M, Tamura T, Sakaeda T, International journal of medical sciences, 8, 3, 210, 215,   2011年03月, 査読有り
  • Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer., Tamura T, Kuwahara A, Kadoyama K, Yamamori M, Nishiguchi K, Inokuma T, Takemoto Y, Chayahara N, Okuno T, Miki I, Fujishima Y, Sakaeda T, International journal of medical sciences, 8, 5, 406, 412,   2011年, 査読有り
  • TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma., Kuwahara A, Yamamori M, Fujita M, Okuno T, Tamura T, Kadoyama K, Okamura N, Nakamura T, Sakaeda T, Journal of experimental & clinical cancer research : CR, 29, 100,   2010年07月, 査読有り
  • Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma., Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Kadoyama K, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T, International journal of medical sciences, 7, 1, 48, 54,   2010年01月, 査読有り
  • Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma., Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T, International journal of medical sciences, 6, 6, 305, 311,   2009年09月, 査読有り
  • Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer., Chayahara N, Tamura T, Yamamori M, Kadowaki Y, Okuno T, Miki I, Tsuda M, Nishisaki H, Maeda T, Inoue Y, Okumura K, Azuma T, Kasuga M, Sakaeda T, Hirai M, American journal of clinical oncology, 32, 1, 56, 60,   2009年02月, 査読有り
  • Role of metallothionein in Helicobacter pylori-positive gastric mucosa with or without early gastric cancer and the effect on its expression after eradication therapy., Mitani T, Shirasaka D, Aoyama N, Miki I, Morita Y, Ikehara N, Matsumoto Y, Okuno T, Toyoda M, Miyachi H, Yoshida S, Chayahara N, Hori J, Tamura T, Azuma T, Kasuga M, Journal of gastroenterology and hepatology, 23, 8 Pt 2, e334, 9,   2008年08月, 査読有り
  • VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients., Sakaeda T, Yamamori M, Kuwahara A, Hiroe S, Nakamura T, Okumura K, Okuno T, Miki I, Chayahara N, Okamura N, Tamura T, Therapeutic drug monitoring, 30, 4, 497, 503,   2008年08月, 査読有り
  • VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese., Yamamori M, Taniguchi M, Maeda S, Nakamura T, Okamura N, Kuwahara A, Iwaki K, Tamura T, Aoyama N, Markova S, Kasuga M, Okumura K, Sakaeda T, International journal of medical sciences, 5, 2, 80, 86,   2008年04月, 査読有り
  • Relationship of BRAF mutation, morphology, and apoptosis in early colorectal cancer., Yoshida S, Ikehara N, Aoyama N, Shirasaka D, Sakashita M, Semba S, Hasuo T, Miki I, Morita Y, Tamura T, Azuma T, Yokozaki H, Kasuga M, International journal of colorectal disease, 23, 1, 7, 13,   2008年01月, 査読有り
  • Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese., Okuno T, Tamura T, Yamamori M, Chayahara N, Yamada T, Miki I, Okamura N, Kadowaki Y, Shirasaka D, Aoyama N, Nakamura T, Okumura K, Azuma T, Kasuga M, Sakaeda T, American journal of clinical oncology, 30, 3, 252, 257,   2007年06月, 査読有り
  • Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines., Boku N, Ohtsu A, Hyodo I, Shirao K, Miyata Y, Nakagawa K, Tamura T, Hatake K, Tanigawara Y, Japanese journal of clinical oncology, 37, 6, 440, 445,   2007年06月, 査読有り
  • The relationship between gastric emptying determined by the breath test and H. pylori., Ebara S, Shirasaka D, Aoyama N, Kachi M, Miki I, Morita Y, Tamura T, Kasuga M, Hepato-gastroenterology, 54, 74, 613, 616,   2007年03月, 査読有り
  • Diagnostic significance of gently sloping depression and irregular margin in superficial elevated colorectal tumors., Nakahara T, Aoyama N, Maekawa S, Tamura T, Shirasaka D, Kuroda K, Nishioka C, Morita Y, Kasuga M, International journal of colorectal disease, 22, 1, 25, 31,   2007年01月, 査読有り
  • Helicobacter pylori eradication therapy on histologic change in the distal esophagus., Toyoda M, Shirasaka D, Aoyama N, Watanabe Y, Miki I, Morita Y, Matsumoto Y, Mitani T, Miyachi H, Tamura T, Kasuga M, Helicobacter, 11, 4, 217, 223,   2006年08月, 査読有り
  • Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan., Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, Toyoda M, Mitani T, Morita Y, Tamura T, Kinoshita S, Okano Y, Kumagai S, Kasuga M, Helicobacter, 11, 4, 243, 249,   2006年08月, 査読有り
  • [A case of unknown primary cancer responding to TS-1]., Kawasaki K, Kamigaki T, Takase S, Maki K, Tamura T, Shirasaka D, Shinoda H, Nakamura T, Kuroda D, Kuroda Y, Gan to kagaku ryoho. Cancer & chemotherapy, 33, 8, 1125, 1128,   2006年08月, 査読有り
  • A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer., Hyodo I, Shirao K, Doi T, Hatake K, Arai Y, Yamaguchi K, Tamura T, Takemiya S, Takiuchi H, Nakagawa K, Mishima H, Japanese journal of clinical oncology, 36, 7, 410, 417,   2006年07月, 査読有り
  • Effects of Helicobacter pylori eradication therapy on gastric emptying measured using the 13C-octanoic acid breath test and the acetaminophen method., Kachi M, Shirasaka D, Aoyama N, Ebara S, Miki I, Morita Y, Tamura T, Kasuga M, Journal of gastroenterology and hepatology, 21, 5, 824, 830,   2006年05月, 査読有り
  • MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer., Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, Koyama T, Okamura N, Miki I, Tamura T, Aoyama N, Kasuga M, Okumura K, Drug metabolism and pharmacokinetics, 21, 2, 126, 132,   2006年04月, 査読有り
  • Comparison of synthetic DNA templates with authentic cDNA templates in terms of quantification by real-time quantitative reverse transcription polymerase chain reaction., Moriya Y, Nakamura T, Okamura N, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Kasuga M, Okumura K, Biological & pharmaceutical bulletin, 29, 3, 535, 538,   2006年03月, 査読有り
  • MDR1 C3435T polymorphism is predictive of later onset of ulcerative colitis in Japanese., Osuga T, Sakaeda T, Nakamura T, Yamada T, Koyama T, Tamura T, Aoyama N, Okamura N, Kasuga M, Okumura K, Biological & pharmaceutical bulletin, 29, 2, 324, 329,   2006年02月, 査読有り
  • HLA-DQB1 locus and gastric cancer in Helicobacter pylori infection., Watanabe Y, Aoyama N, Sakai T, Shirasaka D, Maekawa S, Kuroda K, Wambura C, Tamura T, Nose Y, Kasuga M, Journal of gastroenterology and hepatology, 21, 2, 420, 424,   2006年02月, 査読有り
  • Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy., Nishioka C, Aoyama N, Maekawa S, Shirasaka D, Nakahara T, Tamura T, Fukagawa M, Umezu M, Abe T, Kasuga M, Journal of gastroenterology and hepatology, 20, 10, 1567, 1571,   2005年10月, 査読有り
  • Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma., Miki I, Tamura T, Nakamura T, Makimoto H, Hamana N, Uchiyama H, Shirasaka D, Morita Y, Yamada H, Aoyama N, Sakaeda T, Okumura K, Kasuga M, Therapeutic drug monitoring, 27, 3, 369, 374,   2005年06月, 査読有り
  • Association of VEGF genotype with mRNA level in colorectal adenocarcinomas., Yamamori M, Sakaeda T, Nakamura T, Okamura N, Tamura T, Aoyama N, Kamigaki T, Ohno M, Shirakawa T, Gotoh A, Kuroda Y, Matsuo M, Kasuga M, Okumura K, Biochemical and biophysical research communications, 325, 1, 144, 150,   2004年12月, 査読有り
  • Influence of gastritis on cyclooxygenase-2 expression before and after eradication of Helicobacter pylori infection., Wambura C, Aoyama N, Shirasaka D, Kuroda K, Maekawa S, Ebara S, Watanabe Y, Tamura T, Kasuga M, European journal of gastroenterology & hepatology, 16, 10, 969, 979,   2004年10月, 査読有り
  • Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Tria, Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, Saito H, Iwase H, Tsuji Y, Tamura T, Yamamoto S, Yoshida S, Japanese journal of clinical oncology, 34, 6, 316, 322,   2004年06月, 査読有り
  • Excessive alcohol intake enhances the development of synchronous cancerous lesion in colorectal cancer patients., Maekawa SJ, Aoyama N, Shirasaka D, Kuroda K, Tamura T, Kuroda Y, Kasuga M, International journal of colorectal disease, 19, 2, 171, 175,   2004年03月, 査読有り
  • Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas., Nakahara T, Sakaeda T, Nakamura T, Tamura T, Nishioka C, Aoyama N, Okamura N, Shirakawa T, Gotoh A, Kamigaki T, Ohno M, Kuroda Y, Matsuo M, Kasuga M, Okumura K, Pharmaceutical research, 21, 3, 406, 412,   2004年03月, 査読有り
  • Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics., Tamura T, Yasutake K, Nishisaki H, Nakashima T, Horita K, Hirohata S, Ishii A, Hamano K, Aoyama N, Shirasaka D, Kamigaki T, Kasuga M, Oncology, 67, 5-6, 327, 337,   2004年, 査読有り
  • MDR1, MRP1 and MRP2 genotypes and in vitro chemosensitivity in Japanese patients with colorectal adenocarcinomas., Nishioka C, Sakaeda T, Nakamura T, Moriya Y, Okamura N, Tamura T, Nakahara T, Aoyama N, Kamigaki T, Ohno M, Kuroda Y, Kasuga M, Okumura K, The Kobe journal of medical sciences, 50, 5-6, 181, 188,   2004年, 査読有り
  • MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects., Morita Y, Sakaeda T, Horinouchi M, Nakamura T, Kuroda K, Miki I, Yoshimura K, Sakai T, Shirasaka D, Tamura T, Aoyama N, Kasuga M, Okumura K, Pharmaceutical research, 20, 4, 552, 556,   2003年04月, 査読有り
  • Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan., Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, Okumura K, Kasuga M, European journal of gastroenterology & hepatology, 15, 1, 27, 33,   2003年01月, 査読有り
  • Relationship between gastric ulcer and Helicobacter pylori VacA detected in gastric juice using bead-ELISA method., Shirasaka D, Aoyama N, Sakashita M, Kuroda K, Maekawa S, Wambura CM, Miyamoto M, Tamura T, Yahiro K, Wada A, Kurazono H, Hirayama T, Kasuga M, Helicobacter, 7, 5, 281, 286,   2002年10月, 査読有り
  • Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects., Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M, Kasuga M, Okumura K, Biological & pharmaceutical bulletin, 25, 10, 1356, 1359,   2002年10月, 査読有り
  • Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin., Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, Kasuga M, Okumura K, Pharmaceutical research, 19, 10, 1581, 1585,   2002年10月, 査読有り

MISC

  • 進行・再発大腸癌化学療法の現状と論点, 田村 孝雄, 近畿大学医学雑誌, 39, 1-2, 3, 11,   2014年06月
  • 切除不能大腸癌に対するFOLFOX+bevacizumab(Bev)とFOLFIRI+Bevの第III相試験WJOG4407G, 田村 孝雄, 山崎 健太郎, 奥野 達哉, 仁科 智裕, 大石 達郎, 栗本 拓也, 高山 哲治, 根来 裕二, 吉田 元樹, 杉山 敏郎, 柴田 義宏, 安藤 昌彦, 森田 智視, 朴 成和, 兵頭 一之介, 日本癌治療学会誌, 49, 3, 830, 830,   2014年06月
  • FOLFIRI+Cetuximabが著効した大腸癌多発皮膚転移の1例, 門田 智裕, 大須賀 達也, 小川 浩史, 北見 元哉, 石村 恵美, 志柿 泰弘, 中島 英信, 中田 秀史, 角田 力, 平野 誠一, 伊倉 義弘, 岩井 泰博, 吉川 卓郎, 植野 望, 田村 孝雄, Nippon Shokakibyo Gakkai Zasshi, 111, 1, 115, 123,   2014年, 10.11405/nisshoshi.111.115, http://ci.nii.ac.jp/naid/130003383338
    概要:症例は64歳,女性.右側胸部の皮下腫瘤を主訴に受診.各種検査より下行結腸癌・皮膚転移と診断.原発巣の手術後にFOLFIRI+Cetuximab療法が著効し,皮膚転移は消失した.皮膚転移をきたした大腸癌症例に対する治療法選択の上で参考になる1症例と考えられ,原発巣や転移巣におけるEGFR発現様式との関連も含め,文献的考察を加えて報告する.
  • 【臨床現場が知りたい大腸がん薬物治療】 ガイドラインに則った大腸がん薬物治療 その原則 ESMO等、海外のガイドラインを参考にした薬物治療, 田村 孝雄, 臨床腫瘍プラクティス, 8, 4, 338, 343,   2012年11月
    概要:<View Points!>▼本邦で最もよく参照される海外のガイドラインはNCCNとESMOのガイドライン。▼NCCNのガイドラインのフローチャートは治療の全体像を網羅的に把握するのに便利。▼NCCNのガイドラインは年数回改訂されるので、常に最新のエビデンスに基づいた治療方針が参照できる。▼NCCNのガイドラインはエビデンスの使い方のお手本といえる。▼PDQはエビデンスの基となった論文の要約集。▼ESMOのガイドラインを見れば欧州のコンセンサスがよくわかる。▼ESMOのガイドラインはすぐれた総説であり、NCCNのガイドラインと対比して読むと極めて有用。▼NCCNやESMOのガイドラインの注目すべき主張を把握すれば最新の課題が理解できる。(著者抄録)
  • 研修医からの質問Q&A FOLFIRI+BEVによる治療を継続中の盲腸がん症例に、BEVの増量は有効か?, 田村 孝雄, 臨床腫瘍プラクティス, 8, 2, 194, 195,   2012年05月
  • 【年度初めの消化器検査・治療「知っ得」レッスン2012】 再発・進行胃がんに対する化学療法 分子標的薬を併用した治療法も理解する, 田村 孝雄, 消化器最新看護, 17, 1, 11, 19,   2012年04月
  • 食道がん化学放射線療法におけるフルオロウラシル血漿中濃度と長期予後(一般演題(口頭)39,がん薬物療法(入院化学療法)(1)他,Enjoy Pharmacists' Lifestyles), 桑原 晶子, 山森 元博, 三木 生也, 中村 任, 西口 工司, 田村 孝雄, 片岡 和三郎, 平井 みどり, 栄田 敏之, 日本医療薬学会年会講演要旨集, 21,   2011年09月09日, http://ci.nii.ac.jp/naid/110008909441
  • 研修医からの質問Q&A 経口摂取困難症例に対する胃がん化学療法の1st lineは?, 田村 孝雄, 高張 大亮, 臨床腫瘍プラクティス, 5, 3, 308, 309,   2009年08月
  • 研修医からの質問 Q&A 胃がんにおける標準的治療はS-1+αの併用療法になっていくと思いますが、経口摂取が困難な切除不能症例における治療戦略はどのようにしたらいいでしょうか?その際に、CDDP+CPT-11の位置付けはどのように考えたらいいでしょうか?, 田村 孝雄, 臨床腫瘍プラクティス, 4, 2, 187, 187,   2008年05月
  • 【最新 消化器がんの化学療法とケア】 進行・再発胃がんに対する化学療法, 田村 孝雄, 消化器肝胆膵ケア, 13, 1, 13, 18,   2008年04月
  • 【最新 消化器がんの化学療法とケア】 大腸がんに対するFOLFOX/FOLFIRI療法を中心とした化学療法 ベバシズマブ併用療法も含めて, 田村 孝雄, 消化器肝胆膵ケア, 13, 1, 19, 25,   2008年04月